Please assess the completion status of the following clinical trial:

Trial Title: Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* The diagnosis of schizophrenia according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV)~* 18～60 years old~* Clozapine resistance was defined as used at least two antipsychotics with different chemical structures with appropriate dosages for a sufficient duration, and recently have received stable dose of clozapine 400 mg or more per day for at least 6 months.~* Signed an informed consent~Exclusion Criteria:~* Patients to be diagnosed according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) for substance abused, development delayed~* Suffering from serious physical disease and can not accept the treatment~* Allergic to sodium valproate, amisulpride, propofol, succinylcholine or atropine~* Participated in any clinical subject within 30 days~* Pregnancy or lactation~* Inability to sign informed consent because of capacity due due to severe mental illness, significant psychomotor agitation or slowness test completion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- sodium valproate with clozapine (Type: EXPERIMENTAL): sodium valproate, dosage form: 250 mg, dosage and frequency:250 mg/d for 1 week, 500 mg/d for week 2 , 1000 mg/d for weeks 3, 4, 5, 6, 7 , 8, 9, 10, 11and 12; clozapine, dosage and frequency:300\~600 mg/d; duration: 12 weeks.~Intervention: Drug: sodium valproate with Clozapine
- Modified electroconvulsive therapy with clozapine (Type: EXPERIMENTAL): 12 times MECT for 12 weeks，once a week for the 12 weeks; clozapine, dosage and frequency:300\~600 mg/d; duration: 12 weeks.~Intervention: Device: modified electroconvulsive therapy(MECT) with Clozapine
- amisulpride (Type: EXPERIMENTAL): amisulpride, dosage form: 200 mg, dosage and frequency:200 mg/d for 1 week, 400 mg/d for week 2,800 mg/d for weeks 3, 4, 5, 6, 7 , 8, 9, 10, 11and 12; clozapine, dosage and frequency:300\~600 mg/d; duration: 12 weeks.~Intervention: Drug: amisulpride with Clozapine
- placebo (Type: PLACEBO_COMPARATOR): The amisulpride and placebo tablets were identical in appearance. One placebo tablet for the first one week, two placebo tablets for the second week, four placebo tablets for weeks 3, 4, 5, 6, 7 , 8, 9, 10, 11and 12; clozapine, dosage and frequency:300\~600 mg/d; duration: 12 weeks.~Intervention: Drug: placebo with Clozapine

Based on this trial design, predict the completion outcome and termination type (if applicable).